{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:15:57Z","timestamp":1793916957340,"version":"4.8.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The global rise of multidrug-resistant (MDR) bacterial infections has exacerbated the need for effective vaccines to prevent these hard-to-treat pathogens. Traditional vaccine approaches have achieved tremendous successes but often fall short for pathogens like\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    (TB), which evades host immunity through complex mechanisms, and for multidrug-resistant ESKAPE bacteria, where antibiotic resistance and antigenic variability complicate effective vaccine development. The COVID-19 pandemic spurred unprecedented advances in vaccine technology \u2013 particularly mRNA vaccines \u2013 reviving interest in novel platforms for bacterial diseases. Here we review next-generation vaccine strategies, focusing on nucleic acid-based platforms such as mRNA, DNA, and self-amplifying RNA (saRNA), as well as viral vector vaccines. We also examine nanoparticle technologies that serve as delivery systems or adjuvant platforms across these approaches. We discuss the unique opportunities of mRNA vaccines to induce both robust antibody and T-cell responses required for intracellular infections like TB, as well as the challenges of antigen discovery and delivery (e.g. lipid nanoparticles). Each platform\u2019s mechanism, immunogenic profile, current development status, and challenges are analyzed, including comparative insights. We highlight recent progress such as mRNA vaccine candidates against TB entering clinical trials and saRNA prototypes protecting against plague in animals. Finally, we provide a perspective on the future of vaccine strategies to combat antimicrobial resistance (AMR) \u2013 emphasizing the integration of multiple platforms, global collaborative efforts, regulatory pathways, and the translational hurdles that must be overcome to bring these next-generation vaccines from bench to bedside.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1709794","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:27:18Z","timestamp":1764916038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Next-generation vaccines against bacterial pathogens: mRNA and beyond"],"prefix":"10.3389","volume":"16","author":[{"given":"Huimin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"108492","DOI":"10.1016\/j.biotechadv.2024.108492","article-title":"Current innovations in mRNA vaccines for targeting multidrug-resistant ESKAPE pathogens","volume":"79","author":"Imani","year":"2025","journal-title":"Biotechnol Adv"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"B3","unstructured":"W.H.O. Antimicrobial resistance\n          \n          \n          \n          2023"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1040105","article-title":"Nanomaterials-based vaccines to target intracellular bacterial pathogens","volume":"13","author":"Files","year":"2022","journal-title":"Front Microbiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/vaccines9030209","article-title":"Multi-valent protein hybrid pneumococcal vaccines: A strategy for the next generation of vaccines","volume":"9","author":"Scott","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/vaccines10050751","article-title":"Vaccination against bacterial infections: challenges, progress, and new approaches with a focus on intracellular bacteria","volume":"10","author":"Osterloh","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1282183","article-title":"Vaccine development: obligate intracellular bacteria new tools, old pathogens: the current state of vaccines against obligate intracellular bacteria","volume":"14","author":"van Schaik","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/vaccines13060588","article-title":"Next-generation vaccine platforms: integrating synthetic biology, nanotechnology, and systems immunology for improved immunogenicity","volume":"13","author":"Eslami","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1332939","article-title":"The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects","volume":"15","author":"Lu","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.01.019","article-title":"An overview of current accomplishments and gaps of COVID-19 vaccine platforms and considerations for next generation vaccines","volume":"112","author":"Kale","year":"2023","journal-title":"J Pharm Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/vaccines12121345","article-title":"Vaccine strategies against RNA viruses: current advances and future directions","volume":"12","author":"Hsiung","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3390\/vaccines11121737","article-title":"mRNA and adenoviral vector vaccine platforms utilized in COVID-19 vaccines: technologies, ecosystem, and future directions","volume":"11","author":"Okuyama","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00303-2","article-title":"The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline","volume":"4","author":"Frost","year":"2023","journal-title":"Lancet Microbe"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-025-02070-z","article-title":"Challenges and opportunities in mRNA vaccine development against bacteria","volume":"10","author":"Aernout","year":"2025","journal-title":"Nat Microbiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/vaccines9020147","article-title":"SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.13083","article-title":"Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2","volume":"10","author":"Salleh","year":"2022","journal-title":"PeerJ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/pharmaceutics15071972","article-title":"Recent advancement in mRNA vaccine development and applications","volume":"15","author":"Al Fayez","year":"2023","journal-title":"Pharmaceutics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41541-023-00672-4","article-title":"Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa","volume":"8","author":"Wang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/vaccines10071100","article-title":"Pseudomonas aeruginosa: recent advances in vaccine development","volume":"10","author":"Killough","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-4742-4_16","article-title":"Lipid nanoparticles for the delivery of mRNA","author":"Paroor","year":"2965","journal-title":"Methods Mol Biol 2025"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202500605","article-title":"Nanobody-decorated lipid nanoparticles for enhanced mRNA delivery to tumors in vivo","volume":"14","author":"Escude Martinez de Castilla","year":"2025","journal-title":"Adv Healthc Mater"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2469333","DOI":"10.1080\/21645515.2025.2469333","article-title":"RNA vaccines: The dawn of a new age for tuberculosis","volume":"21","author":"Li","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1238649","article-title":"Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490044","article-title":"mRNA-based platform for preventing and treating Staphylococcus aureus by targeted staphylococcal enterotoxin B","volume":"15","author":"Luo","year":"2024","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00775-24","article-title":"mRNA-LNP vaccines combined with tPA signal sequence elicit strong protective immunity against Klebsiella pneumoniae","volume":"10","author":"Huang","year":"2025","journal-title":"mSphere"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41598-024-84823-0","article-title":"Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii","volume":"15","author":"Ma","year":"2025","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41541-025-01202-0","article-title":"Intranasal delivery of mRNA expressing newly identified Acinetobacter baumannii antigens protects against bacterial lung disease","volume":"10","author":"Higham","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1062210","article-title":"In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant","volume":"13","author":"Heinen","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.12.032","article-title":"Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions","volume":"33","author":"Kawai","year":"2025","journal-title":"Mol Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/v17040566","article-title":"Self-amplifying RNA: advantages and challenges of a versatile platform for vaccine development","volume":"17","author":"Vallet","year":"2025","journal-title":"Viruses"},{"key":"B35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/vaccines12030318","article-title":"Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19","volume":"12","author":"Silva-Pilipich","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"115419","DOI":"10.1016\/j.addr.2024.115419","article-title":"Advances in the design and delivery of RNA vaccines for infectious diseases","volume":"213","author":"Lokras","year":"2024","journal-title":"Adv Drug Delivery Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1247041","article-title":"A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague","volume":"14","author":"Shattock","year":"2023","journal-title":"Front Microbiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.04.014","article-title":"A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity","volume":"30","author":"McCafferty","year":"2022","journal-title":"Mol Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"101262","DOI":"10.1016\/j.eclinm.2021.101262","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","volume":"44","author":"Pollock","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28077","article-title":"Safety and efficacy of DNA vaccines: plasmids vs. minicircles","volume":"10","author":"Stenler","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2660(05)54011-2","article-title":"DNA vaccine","volume":"54","author":"Cui","year":"2005","journal-title":"Adv Genet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/pharmaceutics6030378","article-title":"Intranasal DNA vaccine for protection against respiratory infectious diseases: the delivery perspectives","volume":"6","author":"Xu","year":"2014","journal-title":"Pharmaceutics"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)88325-9","article-title":"Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection","volume":"16","author":"Lodmell","year":"1998","journal-title":"Vaccine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-022-00624-8","article-title":"Lipid-based delivery systems in development of genetic and subunit vaccines","volume":"65","author":"Bolhassani","year":"2023","journal-title":"Mol Biotechnol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"101020","DOI":"10.1016\/j.eclinm.2021.101020","article-title":"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India","volume":"38","author":"Momin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13567-019-0698-z","article-title":"Recent advances in delivery of veterinary DNA vaccines against avian pathogens","volume":"50","author":"Jazayeri","year":"2019","journal-title":"Vet Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2345019","DOI":"10.1080\/21505594.2024.2345019","article-title":"Co-immunization with DNA vaccines encoding yidR and IL-17 augments host immune response against Klebsiella pneumoniae infection in mouse model","volume":"15","author":"Lv","year":"2024","journal-title":"Virulence"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00100-7","article-title":"DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus","volume":"20","author":"Brouillette","year":"2002","journal-title":"Vaccine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.7.3318-3323.2002","article-title":"DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge","volume":"70","author":"Repique","year":"2002","journal-title":"Infect Immun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/vim.2010.0116","article-title":"Plasmids enriched with CpG motifs activate human peripheral blood mononuclear cells in vitro and enhance th-1 immune responses to hepatitis B surface antigen in mice","volume":"24","author":"Chen","year":"2011","journal-title":"Viral Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1998.18.537","article-title":"Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Th1 phenotype","volume":"18","author":"Kim","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.94","article-title":"Prime-boost approaches to tuberculosis vaccine development","volume":"11","author":"Dalmia","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/vaccines10111946","article-title":"Nanoparticle-based delivery systems for vaccines","volume":"10","author":"Bezbaruah","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41541-021-00330-7","article-title":"Protein-based antigen presentation platforms for nanoparticle vaccines","volume":"6","author":"Nguyen","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40259-023-00627-0","article-title":"Outer membrane vesicle vaccine platforms","volume":"38","author":"Micoli","year":"2024","journal-title":"BioDrugs"},{"key":"B58","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/bios13020189","article-title":"Bacterial membrane mimetics: from biosensing to disease prevention and treatment","volume":"13","author":"Arya","year":"2023","journal-title":"Biosensors (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00352-21","article-title":"Novel pneumococcal protein-polysaccharide conjugate vaccine based on biotin-streptavidin","volume":"90","author":"Guo","year":"2022","journal-title":"Infect Immun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1117714","article-title":"PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity","volume":"12","author":"Silva","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.11.025","article-title":"Assessment of immunogenicity and protective efficiency of multi-epitope antigen-loaded in mannan decorated PLGA nanoparticles against tuberculosis","volume":"114","author":"Amini","year":"2025","journal-title":"J Pharm Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2382725","article-title":"Adjuvant system AS01: from mode of action to effective vaccines","volume":"23","author":"Roman","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"B63","doi-asserted-by":"publisher","first-page":"100588","DOI":"10.1016\/j.bj.2023.03.001","article-title":"Antibody induction in mice by liposome-displayed recombinant enterotoxigenic Escherichia coli (ETEC) colonization antigens","volume":"46","author":"Zhou","year":"2023","journal-title":"BioMed J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2013.254","article-title":"Nanoparticle-detained toxins for safe and effective vaccination","volume":"8","author":"Hu","year":"2013","journal-title":"Nat Nanotechnol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00091-16","article-title":"Auto-assembling detoxified staphylococcus aureus alpha-hemolysin mimicking the wild-type cytolytic toxin","volume":"23","author":"Fiaschi","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/vaccines13020126","article-title":"Revolutionizing nanovaccines: A new era of immunization","volume":"13","author":"Saleh","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3390\/microorganisms10071450","article-title":"Viral vector vaccine development and application during the COVID-19 pandemic","volume":"10","author":"Deng","year":"2022","journal-title":"Microorganisms"},{"key":"B68","doi-asserted-by":"publisher","first-page":"168173","DOI":"10.1016\/j.jmb.2023.168173","article-title":"Highly attenuated poxvirus-based vaccines against emerging viral diseases","volume":"435","author":"Perdiguero","year":"2023","journal-title":"J Mol Biol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3390\/vaccines11020432","article-title":"Adenoviral vector-based vaccine platform for COVID-19: current status","volume":"11","author":"Chavda","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939754","article-title":"Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells","volume":"40","author":"Scriba","year":"2010","journal-title":"Eur J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.60","article-title":"Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis","volume":"17","author":"Mu","year":"2009","journal-title":"Mol Ther"},{"key":"B72","volume-title":"mmunobiology of Adenovirus\u2212Vector Vaccines for MRSA","author":"Orvis","year":"2018"},{"key":"B73","doi-asserted-by":"publisher","first-page":"ftw078","DOI":"10.1093\/femspd\/ftw078","article-title":"Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection","volume":"74","author":"Yang","year":"2016","journal-title":"Pathog Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.064","article-title":"Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice","volume":"30","author":"Seregin","year":"2012","journal-title":"Vaccine"},{"key":"B75","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-020-0157-x","article-title":"Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge","volume":"5","author":"Nguyen","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01246-07","article-title":"Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF","volume":"81","author":"Worgall","year":"2007","journal-title":"J Virol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00569","article-title":"Simultaneous subcutaneous and intranasal administration of a CAF01-adjuvanted chlamydia vaccine elicits elevated IgA and protective Th1\/Th17 responses in the genital tract","volume":"8","author":"Wern","year":"2017","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1522255","article-title":"Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines","volume":"17","author":"Prow","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1345","article-title":"Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections","volume":"10","author":"Elkashif","year":"2021","journal-title":"Clin Transl Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1709794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:27:19Z","timestamp":1764916039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1709794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2025.1709794"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1709794","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"1709794"}}